This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

IASLC LALCA, Mexico City, Mexico,1 7-19 October 2019

Overall survival in patients with EGFR mutation-positive NSCLC receiving sequential afatinib and osimertinib: updated analysis of the GioTag study

Maximilian J. Hochmair, Alessandro Morabito, Desiree Hao, Cheng-Ta Yang, Ross A. Soo, James C-H Yang, Rasim Gucalp, Balazs Halmos, Lara Wang, Angela Märten, Tanja Cufer

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Related Content

TREATMENT SEQUENCING

GIOTAG: A REAL-WORLD STUDY OF AFATINIB FOLLOWED BY OSIMERTINIB

UPDATED GIOTAG STUDY PUBLICATION

Read the full updated analysis in the journal Future Oncology

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

This video abstract summarizes updated results, including overall survival data, from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations.

6.42

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results

RELATED INFORMATION

Afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

Updated GioTag study summary

Key results from this real-world study of sequential therapy with afatinib followed by osimertinib

FOR HEALTHCARE PROFESSIONALS ONLY